Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer ...

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...

They were treated with a genetically modified HSV-1 in combination with an immunotherapy called nivolumab. The findings, ...

The herpes simplex virus type 1 (HSV-1), which affects almost two‑thirds of the world's population and is generally ...

Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker ...

The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved ...

A recent trial reveals that nivolumab combined with chemotherapy significantly improves survival rates in older patients with advanced Hodgkin lymphoma.

The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable non–small cell lung cancer (NSCLC) in the neoadjuvant and adjuvant ...

Immunotherapy combinations based on nivolumab entail lower costs for grade 3/4 adverse events than those using pembrolizumab, a finding that could inform treatment decisions.

Nivolumab has recently been approved both in combination with fluoropyrimidine- and platinum-based combination chemotherapy and in combination with ipilimumab for the first-line treatment of ...